(Q35114356)

6 August 2017

1 reference

title

Managing the high-risk patient: therapeutic approaches in 2002 (English)

1 reference

https://api.crossref.org/works/10.1016/S1567-5688(03)00005-9

Cardiology and cardiovascular medicine

27 December 2023

main subject

1 reference

https://api.crossref.org/works/10.1016/S1567-5688(03)00005-9

27 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1567-5688(03)00005-9

27 December 2023

author name string

Herbert Schuster

series ordinal

1

1 reference

6 August 2017

National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III)

series ordinal

2

1 reference

6 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12714033

27 December 2023

publication date

1 March 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S1567568803000059?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1567-5688(03)00005-9

https://api.elsevier.com/content/article/PII:S1567568803000059?httpAccept=text/plain

27 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1567-5688(03)00005-9

Atherosclerosis. Supplements

27 December 2023

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

15-20

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Health care and health status and outcomes for patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900005-9

7 January 2021

Identifiers

1 reference

6 August 2017

1 reference